1. Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease
- Author
-
Noah Huizenga, Karen Laliberte, Zachary S. Wallace, Jillian Rosenthal, Reza Zonozi, Eugene P. Rhee, Frank B. Cortazar, and John L. Niles
- Subjects
Male ,030232 urology & nephrology ,Glomerulonephritis, Membranous ,Gastroenterology ,0302 clinical medicine ,Recurrence ,Risk Factors ,Azathioprine ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Medicine ,Cumulative incidence ,Glomerulosclerosis, Focal Segmental ,Incidence ,Incidence (epidemiology) ,Hazard ratio ,Middle Aged ,Absolute neutrophil count ,Drug Therapy, Combination ,Female ,Rituximab ,medicine.symptom ,medicine.drug ,Adult ,medicine.medical_specialty ,Neutropenia ,Fever ,Filgrastim ,Immunology ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Asymptomatic ,Autoimmune Diseases ,03 medical and health sciences ,Rheumatology ,Hematologic Agents ,Sepsis ,Internal medicine ,Humans ,Immunologic Factors ,Cyclophosphamide ,Aged ,Proportional Hazards Models ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,Nephrosis, Lipoid ,Mycophenolic Acid ,medicine.disease ,Methotrexate ,Asymptomatic Diseases ,bacteria ,business - Abstract
OBJECTIVE Late-onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence. METHODS We conducted a single-center retrospective cohort study of 738 adult patients with autoimmune disease who were treated with rituximab to induce continuous B cell depletion. The primary outcome measure was LON, defined as an unexplained absolute neutrophil count of
- Published
- 2020
- Full Text
- View/download PDF